The State Of CRISPR And Gene Editing Presentation

The use of CRISPR-based therapies in clinical settings using electroporation was a highlighted topic of the State of CRISPR and Gene Editing Summit. The focus of this discussion was on MaxCyte's electroporation platform, a tool designed for clinical use that supports cell therapy development. The platform has been used in various applications, including CRISPR gene editing. This session, led by James Brady, explores the potential of CRISPR technology in gene modification for therapeutic purposes and shares real-world examples of MaxCyte's technology advancing cellular therapies. The benefits of MaxCyte's proprietary Flow Electroporation technology were also discussed. The aim was to offer valuable insights into the future of CRISPR therapies for researchers, clinicians, and therapy developers.